Artisan Partners Limited Partnership Purchases New Shares in Heartflow, Inc. $HTFL

Artisan Partners Limited Partnership acquired a new position in shares of Heartflow, Inc. (NASDAQ:HTFL) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 499,622 shares of the company’s stock, valued at approximately $16,817,000. Artisan Partners Limited Partnership owned about 0.60% of Heartflow as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of HTFL. TD Asset Management Inc acquired a new stake in shares of Heartflow in the third quarter valued at approximately $2,692,000. Vanguard Group Inc. bought a new stake in shares of Heartflow during the third quarter worth $48,871,000. JPMorgan Chase & Co. acquired a new position in shares of Heartflow during the third quarter valued at $13,887,000. Board of Trustees of The Leland Stanford Junior University bought a new position in Heartflow in the third quarter valued at about $10,510,000. Finally, Lisanti Capital Growth LLC acquired a new stake in Heartflow in the third quarter worth about $982,000.

Insiders Place Their Bets

In other news, Director Julie A. Cullivan sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $27.32, for a total transaction of $218,560.00. Following the completion of the transaction, the director directly owned 36,413 shares of the company’s stock, valued at $994,803.16. This trade represents a 18.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey C. Lightcap acquired 40,000 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was acquired at an average cost of $26.34 per share, for a total transaction of $1,053,600.00. Following the transaction, the director owned 40,000 shares of the company’s stock, valued at $1,053,600. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold 2,095,715 shares of company stock worth $58,533,709 in the last 90 days.

Wall Street Analyst Weigh In

HTFL has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their price objective on shares of Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Canaccord Genuity Group upped their price objective on Heartflow from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Wells Fargo & Company initiated coverage on Heartflow in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 target price on the stock. Finally, Stifel Nicolaus boosted their target price on Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.50.

Heartflow Stock Down 3.9%

Shares of NASDAQ:HTFL opened at $23.16 on Friday. The firm has a market cap of $1.97 billion and a price-to-earnings ratio of -12.80. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $41.22. The company’s fifty day simple moving average is $29.09 and its 200 day simple moving average is $31.22.

Heartflow Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.